



Published in final edited form as:

*Nat Rev Neurosci.* 2009 August ; 10(8): 549–560. doi:10.1038/nrn2683.

## The genetic and molecular regulation of sleep: from fruit flies to humans

**Chiara Cirelli**

Department of Psychiatry, University of Wisconsin, Madison, WI 53719, USA

### Abstract

It has been known for a long time that genetic factors affect sleep quantity and quality. Genetic screens identified several mutations that affect sleep across species, pointing to an evolutionary conserved regulation of sleep. Moreover, it has also been recognized that sleep affects the expression of genes. These findings have given valuable clues about the molecular underpinnings of sleep regulation and function that might lead the way to more efficient treatments for sleep disorders.

### Introduction

Studies with twins in the 1930's suggested for the first time that sleep is, to some extent, under genetic control. In 1992 *PRNP*, which codes for the prion protein PRNP, was the first specific gene linked to a human sleep disorder, fatal familial insomnia<sup>1</sup> and was later on shown to affect sleep regulation in mice<sup>2,3</sup>. In 1999 the hypocretin/orexin system was implicated in human narcolepsy through genetic studies in dogs<sup>4</sup> and mice<sup>5</sup>. Since then, other genes have been linked to human sleep disorders or have been shown to affect sleep in animals across species, suggesting that some of the core mechanisms underlying sleep and its regulation are conserved. Recently, molecular studies have also identified hundreds of brain transcripts across species that change their expression level between sleep and waking, suggesting that the functional consequences of sleep are also shared across species. Thus, specific genes can profoundly affect sleep and, conversely, sleep can influence brain gene expression.

The recent progress in identifying sleep genes and sleep-dependent expression patterns was driven by multiple experimental approaches, from classical mutagenesis screening in flies, quantitative trait loci (QTL) analysis in mice, genome-wide association studies in humans to extensive transcriptomic analysis in flies and rodents (Box 1).

#### Box 1

##### Methods to identify genes affecting sleep phenotypes

Several strategies can be used. In reverse genetics a candidate gene is mutated first, and then the effects of the mutation on sleep are assessed (from genotype to phenotype). Candidate genes are chosen based on their known function, which makes them likely to be relevant for sleep. In forward genetics the starting point is the phenotype, and a significant part of the work involves going back to the genotype to identify the responsible gene (from phenotype to genotype). This approach is unbiased, and novel genes can be discovered. Forward genetic methods include quantitative trait loci (QTLs) analysis and mutagenesis screening, which can complement each other. Quantitative trait loci (QTLs) are stretches

of genome closely linked to the genes that underlie the phenotype under study. QTL analysis starts with the crossing between two inbred mouse strains that differ in the trait under study, and maps a chromosomal region segregating with the phenotype in the progeny. The region may contain either a single “major” gene (that can explain >25% of the genetic variance of a trait) or several genes with small effects. In mutagenesis screenings random small mutations are induced over the entire genome. Insertional mutagenesis uses transposable elements (in flies) to induce mutations, while chemical mutagenesis uses ethylmethane sulfonate (EMS, in flies) or N-ethyl N-nitrosourea (ENU, in mice). In these studies hundreds/thousands of mutated flies or mice are usually screened for the phenotype of interest, and behavioral analysis is preferred because less time consuming and less expensive <sup>120</sup>.

This Review will first describe the multiple aspects of sleep that can be grouped in circadian and homeostatic sleep phenotypes, and then discuss some of the genes whose mutations significantly affect sleep in flies, mice, and humans. Overall, these genes can be broadly subdivided into four major functional categories: ion channels, circadian regulation, neurotransmission, and other signaling pathways/hormones. Finally, the effects of sleep on brain gene expression will be reviewed, and the functional categories of waking-related and sleep-related transcripts will be discussed.

## Sleep phenotypes

Studies in the 1930’s reported that some sleep phenotypes have higher concordance in monozygotic than in dizygotic twins, suggesting some genetic basis (reviewed in <sup>6</sup>). A first requirement for studying this phenomenon is to define and characterize the phenotypes of sleep: how much, how well, and when we sleep (Fig 1). It is noteworthy, that sleep phenotypes can change independently of each other. For instance, sleep can be poorly restorative and yet of “normal” duration. Similarly, in some circadian sleep disorders the preferred bedtime occurs too early or too late, but daily sleep amount and sleep quality are preserved.

Sleep is tightly regulated by two sets of mechanisms that work partly independent of each other: the circadian and homeostatic mechanism (Fig 1A). The circadian mechanism reflects how sleep propensity changes during the 24 hours, and its function is to restrict sleep to a time of day that is ecologically appropriate. In mammals, the suprachiasmatic nucleus (SCN) of the hypothalamus is responsible for circadian (circa-diem, approximately 24 hours) rhythms. After SCN lesions sleep is no longer consolidated in one major phase (the day in rodents, the night in flies and humans), but occurs in short episodes throughout the 24-hour period. The homeostatic mechanism, instead, reflects how sleep pressure accumulates during wakefulness and is discharged when we sleep. If waking is prolonged beyond its physiological duration (~16 hours in humans) sleepiness increases, performance decreases, and when sleep is finally permitted its duration and/or intensity are greater than in baseline conditions. Sleep homeostasis is controlled centrally by the interaction between sleep-promoting neuronal groups in hypothalamus and basal forebrain, and waking-promoting groups in hypothalamus and brainstem. Sleep need is also locally regulated: brain regions that have undergone synaptic potentiation (e.g. after learning) show larger slow waves, reflecting deeper sleep states <sup>7</sup>.

Sleep quantity (duration of total sleep and of its various phases) and quality (latency to sleep, brief arousals after sleep onset, amount of large slow waves) also belong to the sleep phenotypes that have to be accounted for when sleep regulation and function are assessed (Fig 1B).

Sleep quantity and quality in humans is assessed by measuring brain electrical activity with the electroencephalogram (EEG). EEG patterns change predictably depending on behavioral state, from the low voltage fast activity of waking and REM sleep to the slow waves and

spindles of NREM sleep (Fig. 1B). More refined information about sleep quality comes from the analysis of the EEG power spectrum, which measures the extent to which specific frequency bands are represented in the EEG signal (Fig. 1B). Interestingly, recent studies found strong heritability of the sleep EEG power spectrum<sup>8,9</sup> (Box 2). Evidence for the heritability of other sleep traits is listed in Supplementary Table 1.

### Box 2

#### Heritability of the sleep and waking EEG

Two recent reports found strong heritability of the sleep EEG power spectrum<sup>8,9</sup>, extending previous results in normal sleepers (not twins), which showed that the sleep EEG is very consistent across nights in the same subject, but varies considerably from one individual to another. Other studies found that the trait-like nature of the human sleep EEG is evident at most frequencies below 15–16 Hz<sup>121–126</sup>. Heritability is probably not as strong for delta activity, which is significantly affected by sleep/waking history. It is worth mentioning that the spectral composition of the human EEG shows striking heritability also during waking, with estimates ranging from 70 to 90% for most frequency bands<sup>127,128</sup>. The coherence of the waking EEG is also under strong genetic influence<sup>129,130</sup>. In fact, the EEG is among the most heritable traits in humans, although few specific genes have been identified so far. A linkage disequilibrium between the beta frequency of the human EEG and a GABA<sub>A</sub> receptor locus has been reported in a rest state with eyes closed, but it is unknown whether this finding is specific for relaxed waking or extends to sleep<sup>131</sup>. Thus, the challenge for the future will be not only to identify which specific genes influence the human EEG, but also to determine to which extent their effects are unique to sleep or waking. It is likely that at least some of the interindividual differences in the human EEG are related to genetic factors that are independent of behavioral state.

The most studied is the EEG delta activity, the EEG power in the 0.5–4.5Hz range during NREM sleep, also called slow wave activity (SWA). The higher the SWA, the deeper is NREM sleep, i.e. the more difficult it is to wake up when a stimulus is delivered<sup>10</sup>. Moreover, the longer the duration of waking, the higher is the level of SWA at sleep onset (refs in<sup>11</sup>). For these reasons delta activity is considered a marker of sleep intensity as well as of sleep need. Sleep in rodents, birds, and other animals is also customarily quantified using EEG analysis, while behavioral criteria are used as indicators of sleep in fish and invertebrates. Indeed, it is worth pointing out that in almost all animals sleep is characterized by quiescence (marine mammals are an exception) and increased arousal threshold. The latter is the single most important feature that distinguishes sleep from “rest” or quiet waking, suggesting that the reduced ability to respond to the environment is a requirement for the restorative function of sleep to occur, and can be captured without the EEG<sup>12</sup>. Thus, the EEG is crucial for a detailed analysis of NREM and REM sleep in many vertebrates, but our understanding of sleep regulation and functions can equally benefit from behavioral analysis, as done in several newly introduced invertebrate animal models (Table 1).

### Sleep studies across species

Studies across in flies, mice and humans have identified genes that affect sleep. These genes can be grouped into four major functional categories (Supplementary Table 2), which will be discussed below after briefly discussing contributions from various species.

#### Studies in flies

Studies over the past 8 years have demonstrated that the fruit fly shows most of the fundamental features of mammalian sleep (Table 1). Flies lend themselves ideally to forward genetic

approaches (Box 1) because their genome is less redundant than mouse or human genomes, which means that a mutation in the fly is more likely to yield a strong phenotype. Recently, the naturally occurring variation in both sleep phenotypes and mRNA expression levels of wild-derived inbred lines has also been used as a promising approach to identify candidate genes<sup>13</sup>. The genetic basis of sleep will also benefit from studies in the zebrafish *Danio rerio* and the roundworm *Caenorhabditis elegans* (Table 1), both of which have recently been shown to have a sleep-like state<sup>14–17</sup>.

### Studies in mice

Almost all mouse genes known to affect sleep have been identified by reverse genetics studies, with more than 70 mutant lines tested so far, starting from two pioneering reports in 1996<sup>2, 18</sup> (Supplementary Table 2). Quantitative trait loci (QTL) analysis (Box 1) has recently succeeded twice, in linking a single mouse gene to a specific frequency of the sleep EEG<sup>19, 20</sup>, while no mouse gene so far has been identified using mutagenesis screenings. A few general conclusions can be drawn from these studies. First, most mouse mutant lines show effects on at least one sleep phenotype, which is perhaps not surprising since these lines carry mutations in “candidate” genes. Second, the effects on sleep quantity – if any- are usually small, with increases or, in most cases, decreases in total sleep of ~ 20% or less, due to a decline in NREM or REM sleep. Very few mutations affect both sleep phases, and then almost always in the same direction (prokineticin 2-deficient mice<sup>21</sup> and corticotrophin-releasing hormone overexpressing mice<sup>22</sup> are exceptions; Supplementary Table 2). Third, changes in the response to sleep deprivation, when present, are also usually small, although caution is needed to interpret these results, because most studies do not assess sleep homeostasis in a comprehensive manner.

### Studies of sleep disorders in human

In several cases the genetic basis of human sleep disorders has been clarified, and the identified candidate genes have been tested in animal models. Examples that will be discussed include the hypocretin/orexin system and its role in narcolepsy, and *Period (Per)* genes, whose mutations result in abnormal circadian regulation.

**Ion Channels**—Over the last 3 years, mutagenesis screenings have identified two fly genes with striking effects on fly sleep, namely *Shaker* and *Sleepless*. The first gene, *Shaker*, which was identified with EMS mutagenesis (Box 1), codes for the alpha subunit of a tetrameric potassium channel that passes a voltage-activated fast-inactivating  $I_A$  current<sup>23</sup>. Homologous channels in vertebrates have similar properties and, in both mammals and flies,  $I_A$  plays a major role in the control of membrane repolarization and transmitter release<sup>23</sup>. Flies carrying *minisleep*, or other *Shaker* loss of function mutations, sleep only 2–4 hours every day rather than 8–10 hours, but their circadian and homeostatic regulation of sleep are normal<sup>24</sup>. Moreover, learning and memory in these flies is impaired, and lifespan is reduced, although it is still unclear whether these deficits can be ascribed to reduced sleep<sup>24,25</sup>. *Hyperkinetic* codes for a beta regulatory subunit that interacts with the alpha pore forming subunits coded by *Shaker*. *Hyperkinetic* loss of function mutations also show a short sleeping phenotype, impairment in learning and memory, and reduced life span<sup>25</sup>. In *Hyperkinetic* mutants sleep is not reduced as much as in *Shaker* mutants (by 30–50%), which is expected since *Hyperkinetic* null mutations reduce, but do not abolish, the  $I_A$  current.

*Sleepless*, was identified using insertional mutagenesis<sup>26</sup> (Box 1). *Sleepless* flies, like the most extreme *Shaker* null mutants, sleep only ~ 2 hours a day (~ 85% less than controls), mainly due to a decrease in sleep episode duration. *Sleepless* codes for a glycosyl-phosphatidylinositol-anchored protein with unknown function, and has no obvious vertebrate homolog. *Quiver*, however, a previously identified mutation that affects the  $I_A$  current, is allelic to *Sleepless*, and

*Sleepless* flies have reduced levels of *Shaker*. This suggests that the *Sleepless* short sleeping phenotype is at least in part mediated by the *Shaker* current. There are nevertheless some interesting differences between *Shaker* and *Sleepless* flies, most notably that only the latter show a reduced homeostatic response, as indicated by no changes in sleep duration after sleep deprivation.

Why do mutations affecting the  $I_A$  current decrease sleep duration so significantly? In mammals, neurons in the cortex and thalamus are more hyperpolarized in sleep than in waking<sup>27</sup>, and one possibility is that these mutations may impinge on the core cellular mechanisms of sleep by changing overall neuronal excitability (Fig. 2). Based on sequence similarity, the closest mammalian homologues of the *Drosophila Shaker* gene are the alpha subunits of the Kv1 family of potassium channels, while the Kv2, Kv3, and Kv4 families are more distantly related (“Shaker-like”). Kv1 channels activate in the subthreshold voltage range in many neurons, and can act as extremely diverse regulators of neuronal excitability<sup>28</sup> (Figure 2). Mice lacking the closest mammalian homologue of *Shaker*, *Kv1.2 (Kcna2)*, sleep less. Their short sleeping phenotype, however, is far from being as dramatic as in *Shaker* flies<sup>29</sup>, perhaps because of redundancy - there is one *Shaker* gene in *Drosophila*, but at least 16 genes code for alpha subunits of voltage-dependent potassium channels in mammals<sup>30,31</sup>.

A striking sleep phenotype is observed in double knockout (KO) mice lacking the voltage-dependent potassium channels Kv3.1 and Kv3.3<sup>32</sup>, which sleep less (by 40%), have shorter sleep episodes, an overall decrease in the EEG power spectrum more evident in NREM sleep, and no response to sleep deprivation. These mice are also hyperactive and show motor dysfunction, which may be partly responsible for their sleep fragmentation<sup>32,33</sup>. The mechanism underlying the effect of these mutations on sleep is most likely different from those involved in *Shaker* and *Sleepless* mutants, because Kv3-type channels are mainly expressed in cortical and thalamic GABAergic interneurons, where their presence enables these cells to fire repetitively at high-frequency<sup>34</sup>. Whether human extreme short sleepers have mutations in voltage-dependent potassium channels remains unknown, but in one case of Morvan’s syndrome, a rare autoimmune disorder with central symptoms, marked sleeplessness has been associated with the presence of autoantibodies against voltage-dependent potassium channels<sup>35</sup>.

Another candidate sleep gene that was identified in mice is *Ca<sub>v</sub>3.1*, which codes the alpha1G subunit of the T-type calcium channels. These channels play a crucial role in most of the neuronal oscillations displayed by thalamic and cortical neurons during NREM sleep<sup>36</sup>. Two independent studies have reported a decrease of ~20% in NREM sleep and more frequent brief awakenings, a sign of disrupted sleep, in mutant mice carrying a *Ca<sub>v</sub>3.1* deletion either globally or in most of the thalamus, while cortical deletion had no effect<sup>37,38</sup>. However, detailed experiments to assess the effects of these mutations on the sleep EEG still need to be carried out.

**Circadian regulation**—At the molecular level, circadian genes interact and determine circadian rhythmicity. Most of these genes have been tested for their effects on sleep (Supplementary Table 2). Double KO mice of the circadian genes *cryptochrome1* and *cryptochrome2* sleep more and have higher NREM delta activity, but show little further increase in sleep duration and intensity after sleep deprivation<sup>39</sup>. Other mutations of circadian mouse genes (*Clock*, *brain and muscle ARNT-like protein 1*, *neuronal PAS domain protein 2*, *prokineticin 2*) also result in an abnormal response to sleep deprivation, as do mutations of the fly circadian genes *Cycle* and *Clock* (Table 1). Overall, it appears therefore that circadian mutations not only affect the timing of sleep, as expected, but also its homeostatic regulation.

**Period (Per) genes**—A functional circadian clock seems to require oscillations of Per protein levels and its phosphorylation, and/or its rhythmic nuclear localization (Fig. 3). Flies lacking *Per* have a disrupted rest/activity cycle and reduced sleep, but whether the short sleeping phenotype is due to the specific loss of *Per* remains unclear<sup>40</sup>. Loss of *Per2* in mice (mammals have 3 *Per* genes) also disrupts locomotor activity rhythms; moreover, cortical *Per2* levels change depending on both time of day (high at night) and behavioral state (high in waking)<sup>39,41–43</sup>. Since *Per2* induction is sensitive to the NAD/NADH ratio<sup>44,45</sup> it may reflect the level of brain activity<sup>46</sup>, which varies with sleep and waking. Thus, *Per2* could be an essential part of the central clock as well as of the mechanism that regulates sleep need based on waking duration (Fig. 3). However, studies in animals remain inconclusive, because *Per1*, *Per2*, *Per3*, and double *Per1/Per2* KO mice have normal sleep duration and sleep homeostasis.

Studies in humans, instead, point to an important role for *PERIOD3*, which contains variable-number tandem-repeat polymorphisms in its coding region. Relative to *PER3*<sup>4/4</sup> carriers, *PER3*<sup>5/5</sup> individuals have longer duration of SWS and higher NREM delta activity, the latter also after sleep deprivation<sup>47</sup>. *PER3*<sup>5/5</sup> subjects also show higher alpha and theta EEG activity during waking and REM sleep (both signs of increased sleep pressure), and after total sleep deprivation (but not chronic sleep restriction<sup>48</sup>) are more impaired in executive functioning tasks in the early morning<sup>47,49</sup>. Significant interindividual differences in the cognitive impairment caused by sleep loss have been found before (reviewed in<sup>50</sup>). Recent experiments suggest that these individual differences are also associated with different patterns of neural activation as measured using functional MRI<sup>51</sup>. Further studies are required to confirm that *PER3* plays a crucial role in modulating susceptibility to sleep deprivation.

The human familial advanced sleep phase syndrome (FASPS) is transmitted in a highly penetrant autosomal dominant manner. FASPS subjects have a normal duration of sleep but go to sleep ~ 4-hour earlier than usual (extreme early birds). Some FASPS individuals carry a serine to glycine mutation in *PER2*, and the mutation in vitro affects the ability of casein kinase I epsilon to phosphorylate PER2<sup>52</sup>. The same mutation in mice recapitulates the human FASPS phenotype<sup>53</sup>. A missense mutation in *CSNK1D* (human casein kinase I delta gene) also results in FASPS, and reduces enzymatic activity in vitro<sup>54</sup>. These and other studies show that the extent to which PERIOD proteins are phosphorylated greatly affects their nuclear accumulation and thus influence the endogenous circadian period, suggesting that future proteomic studies can help our understanding of how sleep and circadian rhythms are regulated. Genetic association studies have also suggested a link between delayed sleep phase syndrome (DSPS, extreme night owls) and several genes, including *PER3* (refs in<sup>55</sup>).

**Neurotransmission**—In general, genetic studies have largely confirmed the arousal-promoting role of the noradrenergic, histaminergic, serotonergic, cholinergic and hypocretin/orexin systems (detailed refs in Supplementary Table 2). In some cases, these studies have also revealed a more specific role for some of these systems in regulating certain sleep phenotypes. For instance hypocretins/orexins have been shown to be essential for stabilizing sleep and wakefulness<sup>56</sup>. Indeed narcolepsy, a neurological disorder caused by hypocretins/orexins deficiency, is characterized by the inability to maintain long waking periods, abrupt transitions into NREM sleep, and abnormal intrusions of REM sleep into waking<sup>56</sup>. Canine narcolepsy is an autosomal recessive, fully penetrant, disorder due to a mutation in the gene coding for the hypocretin receptor 2<sup>4</sup>. In mice, a narcoleptic-like phenotype is present in both the *preprohypocretin/orexin* KO mice, where the hypocretins/orexins producing cells are spared but the corresponding peptides are lost, and in the *hypocretin/orexin-ataxin 3* transgenic rats and mice, where both cells and peptides are missing.

Genetic studies have also shown that the noradrenergic and histaminergic systems are important in maintaining arousal, since mice deficient in histamine (*Hdc* KO mice) or

norepinephrine/epinephrine (*Dbh* KO mice) tend to sleep more, and have less trouble in going back to sleep after exposure to mild stress. On the other hand, mice lacking the serotonin transporter SERT or serotonin receptor 1A have 40–50% more REM sleep, in line with the role of serotonin in the regulation of this behavioral state.

Reverse genetics has also clarified the mechanisms by which some drugs affect sleep. For instance, adenosinergic transmission, which is blocked by caffeine, plays an important role in the homeostatic regulation of sleep, and adenosine levels increase during waking and decrease during sleep in cortex and basal forebrain of rats and cats (reviewed in <sup>57</sup>). Mice lacking the adenosine receptor A2AR are insensitive to the wake-promoting effects of caffeine, consistent with the fact that in humans a polymorphism in *A2AR* contributes to individual sensitivity in the effects of caffeine on sleep <sup>57</sup>. In humans, a functional polymorphism in the gene coding for the catabolic enzyme adenosine deaminase (ADA) results in a ~20–30% decrease in enzymatic activity in blood cells, ~50% increase in SWS duration, and ~60% increase in NREM delta activity, with no change in total sleep time <sup>58</sup>. Whether this genetic variation also affects the response to sleep deprivation remains untested.

**Other signaling pathways and hormones**—A variety of molecules have been tested for their effects on sleep, but no systematic analysis of all major signaling pathways has been attempted so far. While it is not possible to provide a comprehensive summary of these studies in the main text (but see Supplementary Table 2), it is clear that a few mutations produce large (40–50%) changes in sleep quantity. They include those affecting RIM1alpha, a protein involved in synaptic vesicle release <sup>59</sup>, and UBE3A, a ubiquitin protein ligase whose null mutation, however, also causes abnormal EEG discharges <sup>60</sup>. Other signaling pathways have been linked to a specific frequency of the sleep EEG. During REM sleep the EEG shows prominent theta activity, which varies greatly in frequency among inbred mouse strains (slow and fast theta strains). By using QTL analysis followed by fine mapping, one study was able to link *Acads* to theta frequency <sup>19</sup>. *Acads* encodes the short-chain acyl-coenzyme A dehydrogenase, an enzyme involved in fatty acid beta oxidation, but the mechanism by which its deficiency can slow down the peak theta frequency (from ~8 to 6 Hz) remains unclear <sup>19</sup>. Another study that used forward, molecular, and reverse genetic approaches showed that *Rarb*, the gene encoding the retinoid acid receptor beta, is important to determine the contribution of delta activity to the EEG during NREM sleep <sup>20</sup>. The mechanism by which this nuclear receptor affects the amount of delta activity, and thus cortical synchrony during sleep, is unclear, but it may depend on its role in development, neural plasticity, and dopaminergic transmission. *Rarb* does not seem to play a role in sleep homeostasis.

**The *Dps1* locus:** A recent study using 25 recombinant inbred mice strains found that the increase in NREM delta activity after sleep deprivation depends on both duration of sleep and genotype. It was found that *Dps1*, a QTL locus on mouse chromosome 13 that contains more than 200 genes, accounts for 49% of the genetic variance in this trait <sup>61,62</sup>. Two follow-up studies identified *Homer1a*, an immediate early gene induced by neuronal activity <sup>63,64</sup>, as a likely candidate gene within *Dps1* <sup>65,66</sup>. The conclusion was based on the consistent and strong induction of *Homer1a* after sleep deprivation in the whole brain of several mice strains <sup>65</sup>, the higher expression of cortical HOMER1A in the strain with the greatest increase in delta activity, and the presence of single nucleotide polymorphisms in *Homer1a* upstream regulatory region <sup>66</sup>. It remains to be proven conclusively whether *Homer1a* plays a role in sleep homeostasis. Future studies should show, for instance, that *Homer1a* KO mice have a significantly impaired response to sleep deprivation. Since *Dps1* contains numerous genes, it is also possible that other major candidates will be identified within this locus. Flies lacking the single *Drosophila* *Homer* gene are hyperactive and show defects in courtship behavior, but whether their sleep regulation is abnormal is unknown <sup>67</sup>.

## Studies in humans: genetic control of sleep disorders

### Fatal familial insomnia (FFI)

Fatal familial insomnia (FFI) is a rare autosomal dominant disease due to a point mutation at codon 178 of *PRNP*. The same mutation is also present in patients affected by the familial form of Creutzfeldt-Jakob disease (CJD), another prion disease with extensive cortical, rather than thalamic, degeneration, and in which dementia, rather than insomnia, is the main clinical feature. In FFI patients, codon 129 on the mutated allele codes for a methionine, while in CJD patients it codes for a valine (reviewed in <sup>68,69</sup>). FFI is characterized by a decrease in sleep spindles, sleep fragmentation, reduction in total sleep time, loss of the circadian regulation of sleep, disappearance of SWS, and intrusion of a REM-like state into wakefulness. FFI patients show accumulation of abnormal PRNP in the brain, but PRNP levels do neither correlate with the severity of the disease, nor with the extent of neuronal degeneration. It is also unclear to what extent the sleep disturbances contribute to the death of FFI patients. Mice lacking *Prnp* have fragmented sleep, suggesting that the normal protein may promote sleep consolidation <sup>2,3</sup>. Sleep problems also exist in CJD patients, and transgenic mice carrying the mouse homolog of the human D178N/V129 mutation show a large decrease in REM sleep and periods of a “mixed” state that cannot be easily classified as either sleep or waking <sup>70</sup>.

### Narcolepsy

While in dogs and mice narcolepsy is genetically determined, non-genetic factors play a major role in human narcolepsy, as suggested by its low (~30%) concordance in monozygotic twins. No association has been found between human narcolepsy and polymorphisms in the genes of the hypocretin/orexin system, and so far only one case of narcolepsy with an unusually early onset has been associated with a mutation in *preprohypocretin* <sup>71</sup>. Yet, most patients with narcolepsy-cataplexy have low or undetectable levels of hypocretins, and narcolepsy is strongly associated with human leucocyte antigen (HLA) alleles, in particular HLA *DQB1\*0602*. This suggests that the deficit in hypocretinergic neurotransmission in human narcolepsy could be due to an autoimmune attack <sup>72</sup>. Consistent with this, a recent genome-wide association study found that narcolepsy is associated with the T-cell receptor alpha locus <sup>73</sup>.

**Restless leg syndrome (RLS)**—RLS is a common sleep disorder often characterized by periodic limb movements during sleep. RLS can be familial (autosomal dominant in up to 1/3 of cases). Although dopaminergic agonists are used to treat primary RLS, no association has been found between this disorder and genes involved in dopaminergic transmission. Instead, recent genome-wide case-control studies identified 4 predisposing loci on chromosomes 2p, 6p, 9p and 15q. One locus is within the homeobox gene *MEIS1*, which is involved in limb development. The second within *BTBD9*, whose function may be related to iron storage, the third between the gene coding for the kinase *MAP2K5* and *LBXCOR1*, a homeodomain transcription factor important for the development of GABAergic interneurons in the dorsal horn of the spinal cord, and the fourth within *PTPRD* (protein tyrosine phosphatase receptor type delta) <sup>74,75</sup>. A second genome-wide association study also found an association between *BTBD9* and RLS with period limb movements <sup>76</sup>. Together, the 4 loci may explain more than 50% of the risk for RLS in individuals with European ancestry.

**Obstructive sleep apnea syndrome (OSAS)**—OSAS, a common disorder characterized by recurrent episodes of apnea/hypopnea (no or reduced airflow) during sleep, is also to some extent under genetic control. The genetic basis of this disorder, however, is difficult to study, because many of the risks factors for OSAS, including obesity and alterations of the craniofacial morphology, are also under genetic control <sup>77</sup>.



## Effects of normal sleep and waking on brain gene expression

It is well established that brains of sleeping and awake animals differ in terms of patterns of neural activity, content of many neurotransmitters and neuromodulators, metabolism, and ability to react to external stimuli. Recent whole-genome transcriptomic studies have now revealed that brains of sleeping and awake animals also differ at the molecular level. In rats, mice, flies, and sparrows hundreds of brain transcripts change their level of expression between sleep and wakefulness<sup>41,65,78–86</sup>. In the most tested species so far, rats and mice, these changes occur mainly in the cerebral cortex, cerebellum, and hypothalamus, but also other brain areas. For instance, in one study up to ~5% (752 of 15,459) of the transcripts tested in the cerebral cortex was up- or down-regulated in rats that had slept for 8 hours relative to rats that had been spontaneously awake or sleep deprived for 8 hours<sup>41</sup>. A similar number of cortical transcripts changed their expression because of time of day independent of behavioral state, suggesting that day/night time and sleep/wakefulness influence cortical gene expression to a similar extent<sup>41</sup>. In general, across studies, there are as many “sleep” transcripts (with higher expression during sleep relative to waking) as there are “waking” transcripts. This result suggests that, despite being usually associated with behavioral inactivity, sleep is far from being a quiet state at the cellular level. Most importantly, sleep-related and wakefulness-related transcripts belong to different functional categories, suggesting that the two behavioral states may favor different cellular processes<sup>41</sup>. Moreover, several of the molecular correlates of sleep and wakefulness first identified in rats and mice have subsequently been found in fruit flies and/or sparrows (Fig. 4). The overlap in some major gene categories is remarkable considering that these studies differ not only with respect to the animal species that was tested, but also in terms of design (e.g. sleep deprived vs. spontaneously awake animals), duration of wakefulness (3–8 hours), brain region, and statistical approach.

### Waking-related transcripts

Three functional categories of transcripts are most consistently increased during waking and short-term sleep deprivation relative to sleep (Fig. 4). The first group comprises genes involved in energy metabolism, including those coding for mitochondrial proteins, glucose transporters, and proteins related to glycogen metabolism<sup>86–89</sup>. Their up-regulation may represent a mechanism by which the brain responds to the high energy requirements of wakefulness. This response, however, does not seem to persist when sleep deprivation is prolonged for more than a few hours<sup>80,90</sup>. Imaging studies in animals<sup>91</sup>, normal human subjects<sup>92</sup>, and FFI patients<sup>93</sup> also show either no change or a decrease in cerebral metabolic rate after prolonged sleep loss.

The second group of waking-related transcripts codes for proteins involved in the response to cellular stress, including heat shock proteins and chaperones<sup>41,78,79,82,83,85,86</sup>. This suggests that the absence of sleep may indeed represent a cellular stress for brain cells. In support of this hypothesis, in the mouse cerebral cortex a few hours of sleep deprivation induce the “unfolded protein response”, a global stress response that involves the induction of the chaperone BiP in the endoplasmic reticulum, which promotes the degradation of misfolded proteins, and a decrease in protein synthesis<sup>94</sup>. Importantly, there are no major signs of brain cellular damage after prolonged waking (refs in<sup>95,96</sup>), an indication that the stress response must be protective. This is consistent with the observation that mutant flies unable to mount a strong stress response during sleep deprivation die of sleep loss earlier than controls<sup>97</sup>.

The third group of wakefulness-related transcripts plays a role in synaptic plasticity, and more specifically in synaptic potentiation<sup>41,65,79,86,98</sup>. Overall, the induction of these genes suggests that synaptic potentiation is favored during wakefulness relative to sleep. Consistent with this, recent experiments in flies and rats show that molecular and electrophysiological markers of

net synaptic potentiation prevail in waking, while markers of net synaptic depression are present in sleep<sup>99–101</sup>.

### Sleep-related transcripts

Some of the transcripts with increased expression during sleep are involved in protein synthesis<sup>41,84–86</sup>(Fig. 4). These findings are in agreement with previous studies that identified a positive correlation between sleep and protein synthesis<sup>102–107</sup>. Whether sleep favors protein synthesis globally, or enhances the synthesis of specific classes of proteins, is still unclear.

Another group of sleep-related transcripts includes *CamK4* (calmodulin-dependent protein kinase IV), a gene that has recently been involved in synaptic scaling<sup>108</sup>, and other genes that have been associated with synaptic depression and depotentiation, such those coding for calcineurin, FK506 binding protein 12, inositol 1,4,5-trisphosphate receptor and amphiphysin II<sup>41</sup>. Thus, while wakefulness is the appropriate time for memory acquisition and synaptic potentiation, sleep may favor complementary aspects of plasticity, such as synaptic consolidation and/or downscaling. An involvement of sleep in such processes is suggested by behavioral and physiological experiments showing that sleep improves the performance of different learning tasks<sup>109,110</sup>. At this stage, however, the mechanism by which sleep enhances performance is still debated. One idea is that sleep consolidates synapses activated by learning during the previous waking period, perhaps through mechanisms that require cortical spindle activity and the slow waves of NREM sleep<sup>111,112</sup>. Another possibility is that, since wakefulness is associated with a diffuse potentiation of synaptic circuits that results in a net increase in synaptic weight, sleep produces a generalized depression of synapses. This downscaling would benefit the brain because it decreases the energetic cost of synaptic activity, eliminates weak and ineffective synapses, reduces cellular stress and increases signal to noise ratios<sup>113</sup>.

Finally, a large group of sleep-related transcripts is involved in membrane trafficking and maintenance<sup>41,84–86</sup>. Some of these transcripts are involved in exocytosis and neurotransmitter release, others in synaptic vesicle recycling, tethering/docking of vesicles to their target organelles, and cycling between trans-Golgi network and plasma membrane. Other transcripts are important for the synthesis/maintenance of membranes in general and of myelin in particular, including oligodendrocytic genes coding for myelin structural proteins, myelin-related receptors, and enzymes. Also, transcripts with higher expression in sleep code for enzymes involved in the synthesis and transport of cholesterol, a major constituent of myelin and other membranes and an important factor in regulating synaptic efficacy<sup>114,115</sup>. Depletion of cholesterol/sphingolipid leads to instability of surface AMPA receptors and gradual loss of synapses and dendritic spines<sup>116</sup>. Thus, it may not be by chance that sleep seems to be linked to membrane trafficking and cholesterol synthesis on one hand, and to protein synthesis and synaptic homeostasis on the other hand.

### Future directions

There is little doubt that more genes affecting sleep phenotypes will be identified in the near future, and it is reasonable to assume that most mutations will have less striking effects on sleep in mammals than in simpler organisms, since mammalian genomes are redundant. Even in simpler organisms, however, we should not expect single genes to completely abolish sleep or its regulation, because sleep is a complex and highly regulated behavior, present in all the animal species that have been carefully studied so far, suggesting that it has one or more fundamental functions, such as maintaining brain plasticity and saving energy<sup>12</sup>. A similar argument applies to the brain regions that are involved in initiating and maintaining sleep and waking: there are several sleep-promoting and arousal-promoting neural systems, and the

lesion of one or even a few of them does not result in the complete and permanent lack of either sleep or waking.

Sleep genetic studies are bound to contribute further to our understanding of sleep regulation and function but are also challenging. The identification of the mutated gene in animal models or human disorders is becoming faster and cheaper by the day. One major challenge lies in the choice of the phenotype: Which sleep parameters should we measure when searching for “insomnia genes”? Another issue is the large number of subjects required for genome-wide association studies, which may be a limiting factor unless extensive collaborations across sleep centers around the world are initiated. Finally, large-scale mutagenesis screening remains time-consuming and costly in mice, until – in parallel to flies – automatic, high-throughput and yet sensitive methods to assess sleep in hundreds of animals at a time become available.

Nevertheless, as reviewed in this article, some genes with profound effects on sleep have already been identified even in mammals, and others will be discovered. Neurons are more hyperpolarized during sleep than during waking, and mutations that can significantly change the resting membrane potential, the balance between inhibitory and excitatory neurotransmission, and/or the overall neuronal excitability of large sets of neurons are likely to affect quantity and quality of sleep, as *Shaker*, *Sleepless*, and *Kv3.1/Kv3.3* mutants suggest. Also, in flies as well as in mammals, sleep homeostasis reflects not only the duration of prior waking, but also its intensity, and sleep need increases when waking is associated with learning<sup>7,117,118</sup>. Thus, it is likely that mutations in many plasticity-related genes will affect the homeostatic regulation of sleep. Overall, the identification of mutations that change the need for sleep, or make subjects resistant to the negative effects of sleep deprivation, may prove crucial to further our understanding of the functions of sleep.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was funded by NIH grants P20 MH077967 and R01 GM075315. I thank Drs Daniel Bushey, Stephanie Maret and Giulio Tononi for critical comments on the manuscript, and Drs Daniel Bushey, Emmanuel Mignot and David Raizen for providing the pictures for Table 1.

## Glossary terms

### Hypocretin/orexin system

A group of neurons in the posterior hypothalamus that have diffuse projections to the CNS and release hypocretins/orexins. These neuropeptides have been involved in the regulation of sleep and arousal, feeding, and energy metabolism

### Non-rapid-eye-movement sleep

(NREM sleep) One of the two types of sleep observed in mammals and birds. NREM sleep includes slow wave sleep (SWS, also called stages 3+4 or N3), characterized mainly by large slow waves<sup>119</sup>

### REM sleep

The second phase of sleep observed in mammals and birds. In REM sleep the muscle tone is reduced or absent, but the EEG is similar to waking. REM theta activity (4–7Hz) is also present

## References

1. Medori R, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene [see comments]. *N Engl J Med* 1992;326:444–9. [PubMed: 1346338] First study to show that a sleep disorder is caused by a gene mutation.
2. Tobler I, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. *Nature* 1996;380:639–642. [PubMed: 8602267] First study in mice to show that a null mutation affects sleep regulation.
3. Tobler I, Deboer T, Fischer M. Sleep and sleep regulation in normal and prion protein-deficient mice. *J Neurosci* 1997;17:1869–79. [PubMed: 9030645]
4. Lin L, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 1999;98:365–376. [PubMed: 10458611] Seminal study that identifies the autosomal recessive mutation responsible for canine narcolepsy.
5. Chemelli RM, et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. *Cell* 1999;98:437–451. [PubMed: 10481909] This study shows that mice lacking hypocretin/orexin have a narcolepsy-like phenotype.
6. Dauvilliers Y, Maret S, Tafti M. Genetics of normal and pathological sleep in humans. *Sleep Med Rev* 2005;9:91–100. [PubMed: 15737788]
7. Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. *Nature* 2004;430:78–81. [PubMed: 15184907] This study shows for the first time in humans that local changes in sleep intensity as measured by slow wave activity are driven by learning.
8. Ambrosius U, et al. Heritability of Sleep Electroencephalogram. *Biol Psychiatry*. 2008
9. De Gennaro L, et al. The electroencephalographic fingerprint of sleep is genetically determined: a twin study. *Ann Neurol* 2008;64:455–60. [PubMed: 18688819]
10. Blake H, Gerard R. Brain potentials during sleep. *Am J Physiol* 1937;119:692–703.
11. Achermann P, Borbely AA. Mathematical models of sleep regulation. *Front Biosci* 2003;8:s683–93. [PubMed: 12700054]
12. Cirelli C, Tononi G. Is sleep essential? *PLoS Biol* 2008;6:e216. [PubMed: 18752355]
13. Harbison ST, et al. Co-regulated transcriptional networks contribute to natural genetic variation in *Drosophila* sleep. *Nat Genet* 2009;41:371–5. [PubMed: 19234472]
14. Zhdanova IV, Wang SY, Leclair OU, Danilova NP. Melatonin promotes sleep-like state in zebrafish. *Brain Res* 2001;903:263–8. [PubMed: 11382414]
15. Prober DA, Rihel J, Onah AA, Sung RJ, Schier AF. Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. *J Neurosci* 2006;26:13400–10. [PubMed: 17182791]
16. Yokogawa T, et al. Characterization of Sleep in Zebrafish and Insomnia in Hypocretin Receptor Mutants. *PLoS Biol* 2007;5:e277. [PubMed: 17941721]
17. Raizen DM, et al. Lethargus is a *Caenorhabditis elegans* sleep-like state. *Nature* 2008;451:569–72. [PubMed: 18185515]
18. Zhang J, Obal F Jr, Fang J, Collins BJ, Krueger JM. Non-rapid eye movement sleep is suppressed in transgenic mice with a deficiency in the somatotropic system. *Neurosci Lett* 1996;220:97–100. [PubMed: 8981482]
19. Tafti M, et al. Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep. *Nat Genet* 2003;34:320–5. [PubMed: 12796782] First study in mice to use QTL analysis to identify a gene that affects a specific feature of the sleep EEG (theta rhythm during REM sleep).
20. Maret S, et al. Retinoic acid signaling affects cortical synchrony during sleep. *Science* 2005;310:111–3. [PubMed: 16210540]
21. Hu WP, et al. Altered circadian and homeostatic sleep regulation in prokineticin 2-deficient mice. *Sleep* 2007;30:247–56. [PubMed: 17425220]
22. Kimura M, et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. *Molecular Psychiatry*. 2009 in press
23. Schwarz TL, Tempel BL, Papazian DM, Jan YN, Jan LY. Multiple potassium-channel components are produced by alternative splicing at the Shaker locus in *Drosophila*. *Nature* 1988;331:137–42. [PubMed: 2448635]

24. Cirelli C, et al. Reduced sleep in *Drosophila* Shaker mutants. *Nature* 2005;434:1087–92. [PubMed: 15858564] First gene with strong effects on sleep duration identified in flies using mutagenesis screening.
25. Bushey D, Huber R, Tononi G, Cirelli C. *Drosophila* Hyperkinetic mutants have reduced sleep and impaired memory. *J Neurosci* 2007;27:5384–93. [PubMed: 17507560]
26. Koh K, et al. Identification of SLEEPLESS, a sleep-promoting factor. *Science* 2008;321:372–6. [PubMed: 18635795] Second gene with strong effects on sleep duration identified in flies using mutagenesis screening.
27. Steriade M. The corticothalamic system in sleep. *Front Biosci* 2003;8:D878–99. [PubMed: 12700074]
28. Guan D, et al. Expression and biophysical properties of Kv1 channels in supragranular neocortical pyramidal neurones. *J Physiol* 2006;571:371–89. [PubMed: 16373387]
29. Douglas CL, et al. Sleep in *Kcna2* knockout mice. *BMC Biol* 2007;5:42. [PubMed: 17925011]
30. Misonou H, Trimmer JS. Determinants of voltage-gated potassium channel surface expression and localization in mammalian neurons. *Crit Rev Biochem Mol Biol* 2004;39:125–45. [PubMed: 15596548]
31. Yuan LL, Chen X. Diversity of potassium channels in neuronal dendrites. *Prog Neurobiol* 2006;78:374–89. [PubMed: 16716489]
32. Espinosa F, Marks G, Heintz N, Joho RH. Increased motor drive and sleep loss in mice lacking Kv3-type potassium channels. *Genes Brain Behav* 2004;3:90–100. [PubMed: 15005717]
33. Espinosa F, Torres-Vega MA, Marks GA, Joho RH. Ablation of Kv3.1 and Kv3.3 potassium channels disrupts thalamocortical oscillations in vitro and in vivo. *J Neurosci* 2008;28:5570–81. [PubMed: 18495891]
34. Rudy B, McBain CJ. Kv3 channels: voltage-gated K<sup>+</sup> channels designed for high-frequency repetitive firing. *Trends Neurosci* 2001;24:517–26. [PubMed: 11506885]
35. Liguori R, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. *Brain* 2001;124:2417–26. [PubMed: 11701596]
36. Crunelli V, Cope DW, Hughes SW. Thalamic T-type Ca<sup>2+</sup> channels and NREM sleep. *Cell Calcium* 2006;40:175–90. [PubMed: 16777223]
37. Lee J, Kim D, Shin HS. Lack of delta waves and sleep disturbances during non-rapid eye movement sleep in mice lacking alpha1G-subunit of T-type calcium channels. *Proc Natl Acad Sci U S A* 2004;101:18195–9. [PubMed: 15601764]
38. Anderson MP, et al. Thalamic Cav3.1 T-type Ca<sup>2+</sup> channel plays a crucial role in stabilizing sleep. *Proc Natl Acad Sci U S A* 2005;102:1743–8. [PubMed: 15677322]
39. Wisor JP, et al. A role for cryptochromes in sleep regulation. *BMC Neurosci* 2002;3:20. [PubMed: 12495442]
40. Hendricks JC, et al. Gender dimorphism in the role of cycle (BMAL1) in rest, rest regulation, and longevity in *Drosophila melanogaster*. *J Biol Rhythms* 2003;18:12–25. [PubMed: 12568241]
41. Cirelli C, Gutierrez CM, Tononi G. Extensive and divergent effects of sleep and wakefulness on brain gene expression. *Neuron* 2004;41:35–43. [PubMed: 14715133] First genome-wide microarray study to show that hundreds of transcripts in the rat cerebral cortex change their expression because of sleep and waking, independent of circadian time.
42. Franken P, Thomason R, Heller HC, O'Hara BF. A non-circadian role for clock-genes in sleep homeostasis: a strain comparison. *BMC Neurosci* 2007;8:87. [PubMed: 17945005]
43. Wisor JP, et al. Sleep deprivation effects on circadian clock gene expression in the cerebral cortex parallel electroencephalographic differences among mouse strains. *J Neurosci* 2008;28:7193–201. [PubMed: 18614689]
44. Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. *Science* 2001;293:510–4. [PubMed: 11441146]
45. Reick M, Garcia JA, Dudley C, McKnight SL. NPAS2: an analog of clock operative in the mammalian forebrain. *Science* 2001;293:506–9. [PubMed: 11441147]
46. Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. *Science* 2004;305:99–103. [PubMed: 15232110]

47. Viola AU, et al. PER3 polymorphism predicts sleep structure and waking performance. *Curr Biol* 2007;17:613–8. [PubMed: 17346965] First study in humans to identify a gene polymorphism that affects the response to sleep deprivation.
48. Goel N, Banks S, Mignot E, Dinges DF. PER3 polymorphism predicts cumulative sleep homeostatic but not neurobehavioral changes to chronic partial sleep deprivation. *PLoS One* 2009;4:e5874. [PubMed: 19516903]
49. Groeger JA, et al. Early morning executive functioning during sleep deprivation is compromised by a PERIOD3 polymorphism. *Sleep* 2008;31:1159–67. [PubMed: 18714788]
50. Van Dongen HP, Vitellaro KM, Dinges DF. Individual differences in adult human sleep and wakefulness: Leitmotif for a research agenda. *Sleep* 2005;28:479–96. [PubMed: 16171293] Review of the data suggesting a genetic basis for the interindividual variability in the response to sleep loss.
51. Lim J, Choo WC, Chee MW. Reproducibility of changes in behaviour and fMRI activation associated with sleep deprivation in a working memory task. *Sleep* 2007;30:61–70. [PubMed: 17310866]
52. Toh KL, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science* 2001;291:1040–3. [PubMed: 11232563] First study to identify a mutation responsible for FASPS.
53. Xu Y, et al. Modeling of a human circadian mutation yields insights into clock regulation by PER2. *Cell* 2007;128:59–70. [PubMed: 17218255]
54. Xu Y, et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. *Nature* 2005;434:640–4. [PubMed: 15800623]
55. Okawa M, Uchiyama M. Circadian rhythm sleep disorders: characteristics and entrainment pathology in delayed sleep phase and non-24-h sleep-wake syndrome. *Sleep Med Rev* 2007;11:485–96. [PubMed: 17964201]
56. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 2007;8:171–81. [PubMed: 17299454]
57. Landolt HP. Sleep homeostasis: a role for adenosine in humans? *Biochem Pharmacol* 2008;75:2070–9. [PubMed: 18384754]
58. Retyer JV, et al. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. *Proc Natl Acad Sci U S A* 2005;102:15676–81. [PubMed: 16221767] First study in humans to identify a gene polymorphism that affects the duration of NREM sleep and slow wave activity.
59. Lonart G, Tang X, Simsek-Duran F, Machida M, Sanford LD. The role of active zone protein Rab3 interacting molecule 1 alpha in the regulation of norepinephrine release, response to novelty, and sleep. *Neuroscience* 2008;154:821–31. [PubMed: 18495360]
60. Colas D, Wagstaff J, Fort P, Salvat D, Sarda N. Sleep disturbances in Ube3a maternal-deficient mice modeling Angelman syndrome. *Neurobiol Dis* 2005;20:471–8. [PubMed: 15921919]
61. Franken P, Chollet D, Tafti M. The homeostatic regulation of sleep need is under genetic control. *J Neurosci* 2001;21:2610–21. [PubMed: 11306614] This study used QTL analysis to show that sleep need, as measured by the increase in slow wave activity after prolonged waking, is strongly influenced by genetic factors.
62. Andretic R, Franken P, Tafti M. Genetics of sleep. *Annu Rev Genet* 2008;42:361–88. [PubMed: 18983259]
63. Kato A, Ozawa F, Saitoh Y, Hirai K, Inokuchi K. vesl, a gene encoding VASP/Ena family related protein, is upregulated during seizure, long-term potentiation and synaptogenesis. *FEBS Lett* 1997;412:183–9. [PubMed: 9257717]
64. Brakeman PR, et al. Homer: a protein that selectively binds metabotropic glutamate receptors. *Nature* 1997;386:284–8. [PubMed: 9069287]
65. Maret S, et al. Homer1a is a core brain molecular correlate of sleep loss. *Proc Natl Acad Sci U S A* 2007;104:20090–5. [PubMed: 18077435]
66. Mackiewicz M, Paigen B, Naidoo N, Pack AI. Analysis of the QTL for sleep homeostasis in mice: Homer1a is a likely candidate. *Physiol Genomics* 2008;33:91–9. [PubMed: 18171722]
67. Diagana TT, et al. Mutation of *Drosophila* homer disrupts control of locomotor activity and behavioral plasticity. *J Neurosci* 2002;22:428–36. [PubMed: 11784787]


68. Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: what is FFI? *MedGenMed* 2006;8:65. [PubMed: 17406188]
69. Lugaresi E, Provini F. Fatal familial insomnia and agrypnia excitata. *Rev Neurol Dis* 2007;4:145–52. [PubMed: 17943067]
70. Dossena S, et al. Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model. *Neuron* 2008;60:598–609. [PubMed: 19038218]
71. Peyron C, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat Med* 2000;6:991–7. [PubMed: 10973318]
72. Nishino S. Clinical and neurobiological aspects of narcolepsy. *Sleep Med* 2007;8:373–99. [PubMed: 17470414]
73. Hallmayer J, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. *Nat Genet* 2009;41:708–11. [PubMed: 19412176]
74. Winkelmann J, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. *Nat Genet* 2007;39:1000–6. [PubMed: 17637780]
75. Schormair B, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. *Nat Genet* 2008;40:946–8. [PubMed: 18660810]
76. Stefansson H, et al. A genetic risk factor for periodic limb movements in sleep. *N Engl J Med* 2007;357:639–47. [PubMed: 17634447]
77. Kimura M, Winkelmann J. Genetics of sleep and sleep disorders. *Cell Mol Life Sci* 2007;64:1216–26. [PubMed: 17370036]
78. Cirelli C, Tononi G. Gene expression in the brain across the sleep-waking cycle. *Brain Res* 2000;885:303–21. [PubMed: 11102586]
79. Cirelli C, LaVaute TM, Tononi G. Sleep and wakefulness modulate gene expression in *Drosophila*. *J Neurochem* 2005;94:1411–9. [PubMed: 16001966]
80. Cirelli C, Faraguna U, Tononi G. Changes in brain gene expression after long-term sleep deprivation. *J Neurochem* 2006;98:1632–45. [PubMed: 16923172]
81. Terao A, Greco MA, Davis RW, Heller HC, Kilduff TS. Region-specific changes in immediate early gene expression in response to sleep deprivation and recovery sleep in the mouse brain. *Neuroscience* 2003;120:1115–24. [PubMed: 12927216]
82. Terao A, et al. Differential increase in the expression of heat shock protein family members during sleep deprivation and during sleep. *Neuroscience* 2003;116:187–200. [PubMed: 12535952]
83. Terao A, et al. Gene expression in the rat brain during sleep deprivation and recovery sleep: an Affymetrix GeneChip study. *Neuroscience* 2006;137:593–605. [PubMed: 16257491]
84. Zimmerman JE, et al. Multiple mechanisms limit the duration of wakefulness in *Drosophila* brain. *Physiol Genomics* 2006;27:337–50. [PubMed: 16954408]
85. Mackiewicz M, et al. Macromolecule biosynthesis - a key function of sleep. *Physiol Genomics*. 2007
86. Jones S, Pfister-Genskow M, Benca RM, Cirelli C. Molecular correlates of sleep and wakefulness in the brain of the white-crowned sparrow. *J Neurochem* 2008;105:46–62. [PubMed: 18028333]
87. Cirelli C, Tononi G. Differences in gene expression between sleep and waking as revealed by mRNA differential display. *Brain Res Mol Brain Res* 1998;56:293–305. [PubMed: 9602159]
88. Shaw PJ, Cirelli C, Greenspan RJ, Tononi G. Correlates of sleep and waking in *Drosophila melanogaster*. *Science* 2000;287:1834–7. [PubMed: 10710313]
89. Petit JM, Tobler I, Allaman I, Borbely AA, Magistretti PJ. Sleep deprivation modulates brain mRNAs encoding genes of glycogen metabolism. *Eur J Neurosci* 2002;16:1163–7. [PubMed: 12383246]
90. Rhyner TA, Borbely AA, Mallet J. Molecular Cloning of Forebrain mRNAs which are Modulated by Sleep Deprivation. *Eur J Neurosci* 1990;2:1063–1073. [PubMed: 12106067] Pioneer study that used subtractive cDNA cloning to identify rat forebrain transcripts affected by sleep deprivation.
91. Everson CA, Smith CB, Sokoloff L. Effects of prolonged sleep deprivation on local rates of cerebral energy metabolism in freely moving rats. *J Neurosci* 1994;14:6769–78. [PubMed: 7965078]
92. Wu JC, et al. The effect of sleep deprivation on cerebral glucose metabolic rate in normal humans assessed with positron emission tomography. *Sleep* 1991;14:155–162. [PubMed: 1866529]
93. Cortelli P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. *Neurology* 1997;49:126–33. [PubMed: 9222180]

94. Naidoo N, Giang W, Galante RJ, Pack AI. Sleep deprivation induces the unfolded protein response in mouse cerebral cortex. *J Neurochem* 2005;92:1150–7. [PubMed: 15715665]
95. Cirelli C, Shaw PJ, Rechtschaffen A, Tononi G. No evidence of brain cell degeneration after long-term sleep deprivation in rats. *Brain Res* 1999;840:184–93. [PubMed: 10517970]
96. Gopalakrishnan A, Ji LL, Cirelli C. Sleep deprivation and cellular responses to oxidative stress. *Sleep* 2004;27:27–35. [PubMed: 14998234]
97. Shaw PJ, Tononi G, Greenspan RJ, Robinson DF. Stress response genes protect against lethal effects of sleep deprivation in *Drosophila*. *Nature* 2002;417:287–91. [PubMed: 12015603]
98. Hendricks JC, et al. A non-circadian role for cAMP signaling and CREB activity in *Drosophila* rest homeostasis. *Nat Neurosci* 2001;4:1108–15. [PubMed: 11687816]
99. Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. *Nat Neurosci* 2008;11:200–8. [PubMed: 18204445] This study shows that the overall synaptic strength in the rat cerebral cortex increases during waking and decreases during sleep.
100. Gilestro G, Tononi G, Cirelli C. Widespread changes in synaptic markers as a function of sleep and waking in *Drosophila*. *Science* 2009;324:109–112. [PubMed: 19342593]
101. Donlea JM, Ramanan N, Shaw PJ. Use-dependent plasticity in clock neurons regulates sleep need in *Drosophila*. *Science* 2009;324:105–8. [PubMed: 19342592]
102. Reich P, Driver JK, Karnovsky ML. Sleep: effects on incorporation of inorganic phosphate into brain fractions. *Science* 1967;157:336–8. [PubMed: 6028408]
103. Reich P, Geyer SJ, Steinbaum L, Anchors M, Karnovsky ML. Incorporation of phosphate into rat brain during sleep and wakefulness. *J Neurochem* 1973;20:1195–205. [PubMed: 4697880]
104. Voronka G, Demin NN, Pevzner LZ. Total protein content and quantity of basic proteins in neurons and neuroglia of rat brain supraoptic and red nuclei during natural sleep and deprivation of paradoxical sleep. *Dokl Akad Nauk SSSR* 1971;198:974–7. [PubMed: 4327803]
105. Drucker-Colin RR, Spanis CW, Cotman CW, McGaugh JL. Changes in protein levels in perfusates of freely moving cats: relation to behavioral state. *Science* 1975;187:963–5. [PubMed: 167436]
106. Ramm P, Smith CT. Rates of cerebral protein synthesis are linked to slow wave sleep in the rat. *Physiol Behav* 1990;48:749–53. [PubMed: 2082375]
107. Nakanishi H, et al. Positive correlations between cerebral protein synthesis rates and deep sleep in *Macaca mulatta*. *Eur J Neurosci* 1997;9:271–9. [PubMed: 9058047]
108. Ibata K, Sun Q, Turrigiano GG. Rapid synaptic scaling induced by changes in postsynaptic firing. *Neuron* 2008;57:819–26. [PubMed: 18367083]
109. Born J, Rasch B, Gais S. Sleep to remember. *Neuroscientist* 2006;12:410–24. [PubMed: 16957003]
110. Walker MP, Stickgold R. Sleep, memory, and plasticity. *Annu Rev Psychol* 2006;57:139–66. [PubMed: 16318592]
111. Steriade M. Coherent oscillations and short-term plasticity in corticothalamic networks. *Trends Neurosci* 1999;22:337–45. [PubMed: 10407416]
112. Sejnowski TJ, Destexhe A. Why do we sleep? *Brain Res* 2000;886:208–223. [PubMed: 11119697]
113. Tononi G, Cirelli C. Sleep function and synaptic homeostasis. *Sleep Med Rev* 2006;10:49–62. [PubMed: 16376591] This review suggests that a major function of sleep is to reduce synaptic strength in large brain areas, and discusses how sleep could allow synaptic downscaling.
114. Mauch DH, et al. CNS synaptogenesis promoted by glia-derived cholesterol. *Science* 2001;294:1354–7. [PubMed: 11701931]
115. Christopherson KS, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. *Cell* 2005;120:421–33. [PubMed: 15707899]
116. Hering H, Lin CC, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. *J Neurosci* 2003;23:3262–71. [PubMed: 12716933]
117. Ganguly-Fitzgerald I, Donlea J, Shaw PJ. Waking experience affects sleep need in *Drosophila*. *Science* 2006;313:1775–81. [PubMed: 16990546]
118. Huber R, Tononi G, Cirelli C. Exploratory behavior, cortical BDNF expression, and sleep homeostasis. *Sleep* 2007;30:129–39. [PubMed: 17326538]




119. Silber MH, et al. The visual scoring of sleep in adults. *J Clin Sleep Med* 2007;3:121–31. [PubMed: 17557422]
120. Pack AI, et al. Novel method for high-throughput phenotyping of sleep in mice. *Physiol Genomics* 2007;28:232–8. [PubMed: 16985007]
121. Werth E, Achermann P, Dijk DJ, Borbely AA. Spindle frequency activity in the sleep EEG: individual differences and topographic distribution. *Electroencephalogr Clin Neurophysiol* 1997;103:535–42. [PubMed: 9402884]
122. Tan X, Campbell IG, Palagini L, Feinberg I. High internight reliability of computer-measured NREM delta, sigma, and beta: biological implications. *Biol Psychiatry* 2000;48:1010–9. [PubMed: 11082476]
123. Finelli LA, Achermann P, Borbely AA. Individual ‘fingerprints’ in human sleep EEG topography. *Neuropsychopharmacol* 2001;25:S57–62.
124. De Gennaro L, Ferrara M, Vecchio F, Curcio G, Bertini M. An electroencephalographic fingerprint of human sleep. *Neuroimage* 2005;26:114–22. [PubMed: 15862211]
125. Buckelmuller J, Landolt HP, Stassen HH, Achermann P. Trait-like individual differences in the human sleep electroencephalogram. *Neuroscience* 2006;138:351–6. [PubMed: 16388912]
126. Tucker AM, Dinges DF, Van Dongen HP. Trait interindividual differences in the sleep physiology of healthy young adults. *J Sleep Res* 2007;16:170–80. [PubMed: 17542947]
127. van Beijsterveldt CE, Molenaar PC, de Geus EJ, Boomsma DI. Heritability of human brain functioning as assessed by electroencephalography. *Am J Hum Genet* 1996;58:562–73. [PubMed: 8644716]
128. van Beijsterveldt CE, van Baal GC. Twin and family studies of the human electroencephalogram: a review and a meta-analysis. *Biol Psychol* 2002;61:111–38. [PubMed: 12385672]
129. van Beijsterveldt CE, Molenaar PC, de Geus EJ, Boomsma DI. Genetic and environmental influences on EEG coherence. *Behav Genet* 1998;28:443–53. [PubMed: 9926613]
130. Chorlian DB, et al. Heritability of EEG coherence in a large sib-pair population. *Biol Psychol* 2007;75:260–6. [PubMed: 17498861]
131. Porjesz B, et al. Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. *Proc Natl Acad Sci U S A* 2002;99:3729–33. [PubMed: 11891318]
132. Hendricks JC, et al. Rest in *Drosophila* is a sleep-like state. *Neuron* 2000;25:129–38. [PubMed: 10707978]
133. Tobler I, Wigger E, Durr R, Hajnal A. *C.elegans*: a model organism to investigate the genetics of sleep and sleep homeostasis. *Journal of Sleep Research* 2004;13:1.
134. Nitz DA, van Swinderen B, Tononi G, Greenspan RJ. Electrophysiological correlates of rest and activity in *Drosophila melanogaster*. *Curr Biol* 2002;12:1934–40. [PubMed: 12445387]
135. Huber R, et al. Sleep homeostasis in *Drosophila melanogaster*. *Sleep* 2004;27:628–39. [PubMed: 15282997]
136. Jeon M, Gardner HF, Miller EA, Deshler J, Rougvie AE. Similarity of the *C. elegans* developmental timing protein LIN-42 to circadian rhythm proteins. *Science* 1999;286:1141–6. [PubMed: 10550049]
137. Koh K, Evans JM, Hendricks JC, Sehgal A. A *Drosophila* model for age-associated changes in sleep:wake cycles. *Proc Natl Acad Sci U S A* 2006;103:13843–7. [PubMed: 16938867]
138. Hendricks JC, Kirk D, Panckeri K, Miller MS, Pack AI. Modafinil maintains waking in the fruit fly *drosophila melanogaster*. *Sleep* 2003;26:139–46. [PubMed: 12683471]
139. Andretic R, van Swinderen B, Greenspan RJ. Dopaminergic modulation of arousal in *Drosophila*. *Curr Biol* 2005;15:1165–75. [PubMed: 16005288]
140. Crocker A, Sehgal A. Octopamine regulates sleep in *drosophila* through protein kinase A-dependent mechanisms. *J Neurosci* 2008;28:9377–85. [PubMed: 18799671]
141. Kume K, Kume S, Park SK, Hirsh J, Jackson FR. Dopamine is a regulator of arousal in the fruit fly. *J Neurosci* 2005;25:7377–84. [PubMed: 16093388]
142. Wisor JP, et al. Dopaminergic role in stimulant-induced wakefulness. *J Neurosci* 2001;21:1787–94. [PubMed: 11222668]

143. Agosto J, et al. Modulation of GABAA receptor desensitization uncouples sleep onset and maintenance in *Drosophila*. *Nat Neurosci* 2008;11:354–9. [PubMed: 18223647]
144. Graves LA, et al. Genetic Evidence for a Role of CREB in Sustained Cortical Arousal. *J Neurophysiol* 2003;23:23.
145. Renier C, et al. Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. *Pharmacogenet Genomics* 2007;17:237–53. [PubMed: 17496723]
146. Ruuskanen JO, Peitsaro N, Kaslin JV, Panula P, Scheinin M. Expression and function of alpha-adrenoceptors in zebrafish: drug effects, mRNA and receptor distributions. *J Neurochem* 2005;94:1559–69. [PubMed: 16000146]
147. Van Buskirk C, Sternberg PW. Epidermal growth factor signaling induces behavioral quiescence in *Caenorhabditis elegans*. *Nat Neurosci* 2007;10:1300–7. [PubMed: 17891142]
148. Kramer A, et al. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. *Science* 2001;294:2511–5. [PubMed: 11752569]
149. Snodgrass-Belt P, Gilbert JL, Davis FC. Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. *Brain Res* 2005;1038:171–82. [PubMed: 15757633]
150. Kushikata T, Fang J, Chen Z, Wang Y, Krueger JM. Epidermal growth factor enhances spontaneous sleep in rabbits. *Am J Physiol* 1998;275:R509–14. [PubMed: 9688687]
151. Foltenyi K, Greenspan RJ, Newport JW. Activation of EGFR and ERK by rhomboid signaling regulates the consolidation and maintenance of sleep in *Drosophila*. *Nat Neurosci* 2007;10:1160–7. [PubMed: 17694052]
152. Morrow JD, Vikraman S, Imeri L, Opp MR. Effects of serotonergic activation by 5-hydroxytryptophan on sleep and body temperature of C57BL/6J and Interleukin-6-deficient mice are dose and time related. *Sleep* 2008;31:21–33. [PubMed: 18220075]
153. Yuan Q, Joiner WJ, Sehgal A. A sleep-promoting role for the *Drosophila* serotonin receptor 1A. *Curr Biol* 2006;16:1051–62. [PubMed: 16753559]
154. You YJ, Kim J, Raizen DM, Avery L. Insulin, cGMP, and TGF-beta signals regulate food intake and quiescence in *C. elegans*: a model for satiety. *Cell Metab* 2008;7:249–57. [PubMed: 18316030]




**Figure 1.**

Sleep phenotypes. Sleep phenotypes such as regulation, sleep duration (quantity), or sleep intensity (quality) may reflect different aspects of sleep. A) Sleep regulation. Blue areas indicate time of day most conducive to sleep in humans, due to the combined effect of the circadian system, which consolidates sleep during the dark phase, and the homeostatic system, which increases sleep pressure as a function of waking duration. B) Sleep quantity and quality. Top left, night distribution of sleep stages in adult humans. Right, representative EEG traces in waking, NREM sleep and REM sleep. The waking “activated” EEG is dominated by low voltage fast activity in the beta (>13Hz) and alpha (8–13Hz) range. NREM sleep comprises a transitional stage 1 (N1, not shown), when alpha activity disappears, followed by stage 2 (N2), rich in sleep spindles, and then N3 or slow wave sleep (SWS, also called stages 3+4), when the EEG shows prominent slow waves<sup>119</sup>. The higher the number of slow waves, the deeper is NREM sleep, i.e. the more difficult is to wake up. Sleep spindles are waxing and waning oscillations of thalamic origin whose frequency (12–15 Hz) is comprised within the sigma band (12–16Hz), while slow waves are of cortical origin and are comprised within the delta band, also called slow wave activity (SWA, <4.5Hz).




**Figure 2.**

Proposed mechanism for the short sleeping phenotype caused by loss of function mutations of Shaker/Kv1 potassium channels. Normally, the opening of these channels allow  $K^+$  ions to exit the neuron, bringing the membrane potential to more hyperpolarized (more negative) levels, close to the resting membrane potential. Mutations that reduce the total number of these channels, and/or decrease the time the channel can remain open, tend to bring the membrane potential to more positive (depolarized levels), closer to the threshold for firing an action potential (\* in the figure).



**Figure 3.**

Model showing changes in the expression of Period genes (mRNA and protein) as a function of the 24-hour cycle and in response to sleep deprivation (SD): mRNA levels grow during the day, while protein levels peak at night, when Per enters the nucleus and blocks its own expression. These circadian changes are similar regardless of whether the animal is diurnal (like flies, which sleep mainly at night) or nocturnal (like rats, which sleep mostly during the day). Rodents forced to stay awake during the day show increased Per mRNA levels in the cerebral cortex. In both flies and mammals, however, sleep deprivation usually does not reset the circadian clock, i.e. does not cause phase shifts.



**Figure 4.**

Schematic representation of the major functional categories of genes whose expression is higher in the rat brain after several hours of wakefulness (including after 3–8 hours of sleep deprivation) or after several hours of sleep<sup>41,78,87</sup>. F, M, H, S indicate when changes in the same functional category are also present in the brain of fruit flies, mice, Djungarian hamsters (Tom DeBoer, Irene Tobler, Chiara Cirelli, unpublished results) and sparrows, respectively.

**Table 1**

The best characterized non-mammalian animal models currently used in sleep research, together with major similarities and differences relative to sleep in mice and other mammals.

Aspects of sleep documented in mice and other mammals	Fruit fly ( <i>Drosophila melanogaster</i> )	Zebrafish ( <i>Danio rerio</i> )	<i>Caenorhabditis elegans</i>
<b>Behavioral definition of sleep is met</b>	yes: quiescence and increased arousal threshold <sup>88,132</sup>	yes: quiescence and increased arousal threshold <sup>14-16</sup>	yes: quiescence and increased arousal threshold during development (lethargus) <sup>17</sup> ; preliminary evidence for quiescence and increased rest after deprivation in adults <sup>133</sup>
<b>Documented changes in brain activity</b>	yes: brain electrical activity is reliably correlated with behavioral state <sup>134</sup>		
<b>Homeostatic regulation of sleep is present</b>	yes: increase in sleep time, arousal threshold, duration of sleep episodes and decrease in brief awakenings after sleep deprivation; homeostatic regulation largely independent of the circadian clock <sup>88,132,135</sup> ; however, sleep is more fragmented in <i>cycle</i> and <i>Clock</i> mutants, and female (but not male) <i>cycle</i> mutants show exaggerated response to sleep deprivation <sup>40,97</sup>	yes: increase in sleep time, arousal threshold, and duration of sleep episodes after sleep deprivation by electrical stimulation or vibration; weak or no homeostatic response after sleep deprivation by light exposure <sup>14,16</sup>	yes: following deprivation quiescence occurs earlier, is more consolidated; arousal threshold increased relative to baseline <sup>17</sup>
<b>Circadian regulation of sleep is present</b>	yes: sleep mainly at night in entrained light:dark conditions or constant darkness; arrhythmic sleep after lesions of the circadian clock <sup>88</sup>	yes: sleep mainly at night <sup>14-16</sup>	Lethargus is time locked to the expression of <i>Lin-42</i> , the <i>C. elegans</i> ortholog of the circadian gene <i>Period</i> <sup>136</sup>
<b>Changes in brain gene expression associated with sleep and waking</b>	yes: some are similar to those seen in mammals <sup>79,84</sup>		
<b>Changes in sleep parameters with aging</b>	yes: sleep fragmentation in old flies <sup>137</sup>	(not tested?)	(sleep-like state well defined only during larval development)
<b>Drugs and signaling pathways: similarities with mammals</b>	increase in waking with caffeine, modafinil, amphetamines, octopamine (insect equivalent of norepinephrine), increase in sleep with antihistamines <sup>88,132,138,140</sup> - dopamine; a DAT mutation called Fumin (sleepless in Japanese) decreases daily sleep amount by ~ 60% <sup>141</sup> , consistent with reduced NREM sleep in DAT KO mice <sup>142</sup> - GABA; genetic manipulations that decrease GABA transmission result in reduced sleep <sup>143</sup> -cAMP-dependent protein kinaseA (PKA)-CREB activity: inverse relationship with daily sleep amount in flies and mice <sup>98,144</sup> .	increased sleep with melatonin, GABAergic hypnotics, alpha2-adrenergic agonists, histaminergic H1 antagonists <sup>14,145,146</sup>	most major mammalian neurotransmitters present (ACh, glutamate, dopamine, serotonin, GABA) As in mammals, genetic manipulations that increase the EGFR pathway block locomotion and feeding <sup>147</sup> , but untested whether this quiescence is a sleep-like state (i.e. with increased arousal threshold)
<b>Drugs and signaling pathways: differences with mammals</b>	- epidermal growth factor receptor (EGFR) signaling: in mammals, the pathway affects more and/or only the circadian regulation of sleep but not sleep amount <sup>148-150</sup> ; in flies, genetic manipulations that increase/decrease this EGFR pathway increase/decrease sleep amount without affecting its circadian regulation <sup>151</sup> . - serotonin; complex role in mammals, where it may increase/decrease sleep depending on time of day <sup>152</sup> ; sleep-promoting role in flies <sup>153</sup>	unclear whether the hypocretin/orexin system is wake-promoting as in mammals <sup>15</sup> , or sleep-promoting <sup>16</sup>	
<b>Major differences relative to mammals</b>	- REM-like phase not identified - neuroanatomy - some neurochemistry (tyramine/octopamine but no norepinephrine; no hypocretin/orexin homologue identified)	- REM-like phase not identified	- REM-like phase not identified - neuroanatomy - some neurochemistry (tyramine/octopamine but no norepinephrine; no histamine)

Aspects of sleep documented in mice and other mammals	<b>Fruit fly (<i>Drosophila melanogaster</i>)</b>	<b>Zebrafish (<i>Danio rerio</i>)</b>	<b><i>Caenorhabditis elegans</i></b>
<b>Major strengths and limitations as animal model for sleep</b>	<ul style="list-style-type: none"> <li>+ advanced genetics, fast results, cheap</li> <li>+ limited genome redundancy</li> <li>- difficult to perform electrophysiological studies in CNS</li> <li>- genetic screens that target the effects of mutations specifically on the fly brain not yet available</li> </ul>	<ul style="list-style-type: none"> <li>+ advanced genetics</li> <li>+vertebrate; CNS organization more similar to mammals; easily visualized brain cholinergic/monoaminergic/hypocretin cell groups conserved (refs in 16)</li> <li>+ easy drug screening</li> </ul>	<ul style="list-style-type: none"> <li>+ advanced genetics, fast results, cheap</li> <li>+ simple nervous system, neurons/connections fully characterized</li> <li>- in adults quality-high food induces quiescence, but it remains untested whether this state is sleep-like (with increased arousal threshold) and homeostatically regulated 154</li> <li>- high-throughput assay to measure sleep/waking not yet available</li> </ul>